Is Homocysteine Trending?

What the data shows

Search interest in Homocysteine has risen over the period: the yearly high moved from 51 in 2021 to 90 in 2025, against an all-time high of 100 in February 2026.

• Peak interest: February 2026 (index 100)
• Recent level (last 12 weeks): index 84 of 100
• Change, first vs. latest 12 months: +77%
• Period covered: March 2021 – March 2026

Values are Google's relative search index, where 100 is the highest point in the period — not absolute search volume.

About Homocysteine

Homocysteine is an amino acid the body produces when it breaks down protein. Under normal conditions it is cleared quickly, in a process that depends on vitamin B12, vitamin B6 and folate. When any of those are in short supply — through diet, absorption problems, or age — the clearance slows and levels in the blood rise.

It is tracked because elevated levels have been consistently associated with damage to blood vessel walls, increased clotting tendency, and higher rates of cardiovascular and cognitive decline. Most laboratories flag results above roughly 15 µmol/L, while clinicians working in prevention often prefer to see figures well below that. Beyond vitamin status, the levels are affected by kidney function, thyroid function, several medications, smoking and exercise habits, and by a common genetic variant known as MTHFR that changes how efficiently folate is processed.

None of that is new, which makes the shape of the search data the interesting part. Interest has risen in every year of the period without a single flat stretch, and the trend sits near the top of its own five-year range. A biomarker that has been in the clinical literature for decades does not start climbing steadily unless something outside the clinic has changed.

The most plausible explanation is the arrival of consumer biomarker testing. Blood panels that once required a referral are now ordered directly, alongside consumer genetic testing that surfaces MTHFR status to people who would never otherwise have encountered the term. Homocysteine sits at a particular intersection: cheap to measure, easy to understand as a single number, and apparently actionable. That combination reliably generates search traffic. The nature of the queries supports this — a substantial share concerns the distinction between folic acid and methylfolate, which is not a question asked by someone at the start of the subject.

The caveat is the one that matters most here, and it is frequently skipped. The association between elevated homocysteine and cardiovascular risk is well established, but that is not the same as establishing that lowering the number lowers the risk. Several large trials of B-vitamin supplementation reliably reduced homocysteine while failing to deliver the expected reduction in cardiovascular events, which left open the possibility that the marker reflects an underlying problem rather than causing it. The search trend is best read as measuring public attention to a biomarker, and attention and settled evidence are not the same thing.

More in Health

Compare Homocysteine with other health trends.